Introduction
It has been shown that DNA vaccination can elicit both antigen-specific humoral and cell-mediated immune responses, including T-helper (Th) cell and cytotoxic Tlymphocyte (CTL) responses. The immune responses generated by this technique in many experimental animal models can provide protection against infectious agents or malignant tumor cells (reviewed in Ref. 1) . A major limitation of immunization with conventional vaccines is the lack of CTL stimulation. The conventional vaccines stimulate mostly antibody and to varying degrees, Th cell responses. [2] [3] [4] The latter responses frequently fail to eliminate tumors or virally infected cells, while CTLs are more effective. [5] [6] [7] [8] On the other hand, DNA vaccines excel at stimulating CTLs. [9] [10] [11] We used human carcinoembryonic antigen (CEA) as an antigen in mice, where it is not an endogenous protein, with the purpose of studying strategies of DNA vaccination. In humans, CEA is one of the best characterized tumor-associated antigens in terms of its tissue distribution and biochemistry. 12, 13 It is considered a potential target antigen for cancer immunotherapy. type 2 (Th2) response. Antitumor immunity was enhanced when the CEA and IL-12 plasmids were coinjected at the same muscle site, but not at separate sites despite increased serum IL-12 levels. Though the tumor cells expressed neomycin phosphotransferase, mice immunized with vectors encoding that protein (without CEA) were not protected against tumor growth, and produced no CTLs except for low levels when coinjected with an IL-12 vector. Thus, we show that immunity elicited by DNA vaccination against CEA can be biased to a protective type (high Th1 and CTL activity) or nonprotective type (high Th2 and low CTL activity) by i.m. coinjection of cytokine-expressing plasmids. IL-12 appears to act locally, but not systemically, through an adjuvant effect. Gene Therapy (2000) 7, 481-492.
Immunization usually requires use of adjuvants; 15 however, many adjuvants cause undesirable side-effects, such as severe inflammation, which limits or precludes their use in humans. 16 We investigated the adjuvant effect of plasmids encoding a single cytokine on the immune responses elicited by a plasmid encoding human CEA. Thus, we coinjected the CEA plasmid with plasmids encoding mouse IFN␥, IL-12, or IL-4. Though cytokine expression plasmids have been found to enhance or modify immune responses, most of this work has been performed in infectious disease models, [17] [18] [19] [20] and relatively little in tumor models. In our study, a transplantable mouse mastocytoma cell line P815 was stably transfected to express human CEA (CEA/P815). After five weekly plasmid i.m. injections, anti-CEA humoral and anti-CEA/P815 cellular immune responses were detected. This immunity, however, only partially inhibited the growth of CEA/P815 cells. Anti-CEA IgG isotypes, as well as cytokine secretion by spleen cells were analyzed to reveal the dominant type of the immune response (Th1 versus Th2). By this method, we could readily bias the anti-CEA/P815 T cell response to a more protective type (high Th1 and CTL activity) with either IFN␥ or IL-12 vectors, or to a nonprotective type (high Th2 and low CTL activity) with an IL-4 vector. Though circulating levels of IL-12 were detectable after IL-12-vector treatment, coinjection of that vector at the same site as the CEA vec-Gene Therapy tor was required for optimal immunization. The use of cytokine vectors to regulate immunity is discussed.
Results

Construction of expression vectors
Human CEA cDNA (full length) was inserted into the vector pCI-neo, and the resulting plasmid was designated pCI-CEA (Figure 1 ). This vector has the neo gene, encoding neomycin phosphotransferase (NPT). In some experiments we also used pCMV and pCMV-CEA, that do not encode NPT, but are otherwise identical to pCIneo and pCI-CEA, respectively. Cell surface expression of CEA directed by pCI-CEA or pCMV-CEA was confirmed initially by transient transfection of COS-7 cells with these vectors, and analyzed by flow cytometry with anti-CEA mAb (data not shown). Mouse IFN␥ cDNA and mouse IL-4 cDNA were also cloned into the pCI-neo vector, and the resulting vectors were designated pCI-IFN␥ and pCI-IL4, respectively. The plasmid encoding mouse IL-12, designated VR-IL12, was constructed by cloning a segment consisting of p35 cDNA, a synthetic intron (IVS), an internal ribosome entry site (IRES) sequence and p40 cDNA into the VR1255 plasmid ( Figure 1 ).
The in vitro production and secretion of IFN␥, IL-4, and IL-12 were confirmed by transient transfection of COS-7 cells with the respective vectors. In all cases the respective cytokines, as detected by ELISA, were secreted at levels ranging from 100 to 200 ng/ml. The biological activity of these cytokines was confirmed with appropriate bioassays (data not shown).
Detection of anti-CEA IgG antibody and isotyping
To study the effects of the plasmid pCI-CEA and the cytokine-encoding vectors on production of anti-CEA antibodies, groups of DBA/2 mice were injected i.m. with a mixture of pCI-CEA and either a control vector or a cytokine-encoding vector. To induce an optimal immune response to CEA, we adapted a protocol previously demonstrated to be effective by Conry and colleagues. 21 In Figure 1 preliminary experiments, we found that two DNA injections were not sufficient to generate CTL responses, while anti-CEA antibodies were detectable but could be further enhanced by additional injections. Four or five DNA injections were required consistently to generate CTLs and optimal antibody titers. For this reason, all experiments in this study were performed with five DNA injections at weekly intervals. One week after the last injection, serum samples were obtained for quantitation of IgG anti-CEA antibody. It has been shown that the Th1 and Th2 subsets of CD4 + T cells promote different profiles of IgG isotype production. Strong IgG1 production is an important indication of a Th2-dominant immune response, whereas strong IgG2a production reflects a Th1-dominant immune response. 22 As shown in Figure 2a , production of IgG anti-CEA antibodies was elicited by i.m. injection of the CEA vector into mice. Coinjection of pCI-CEA and VR-IL12 increased the production of IgG anti-CEA antibody compared with the group injected with pCI-CEA and control vector. Injection of a mixture of pCI-CEA and pCI-IL4, but not pCI-IFN␥, also induced an increase in the total IgG anti-CEA antibody production.
In all cases, the profiles of IgG1 and IgG2a isotypes in the serum of mice were influenced by injection of a mixture of pCI-CEA and a cytokine vector as compared with a control vector (Figure 2b) . A mixture of pCI-CEA with either pCI-IFN␥ or VR-IL12 induced higher IgG2a levels and lower IgG1 levels, while coinjection of pCI-CEA and pCI-IL4 had the opposite effect (higher IgG1, lower IgG2a), and these changes were statistically significant ( Figure 2b ). These results are consistent with Th1 (IgG2a) and Th2 (IgG1) responses, respectively.
Detection of CTL response against CEA-expressing tumor cells in vitro CTLs play a critical role in cell-mediated immune responses against virally infected cells and tumor cells. 7, 8, 11 The generation of CTLs is highly influenced by the cytokines produced during an immune response. Figure 3 . Seven days after the last of five DNA injections, spleen cells were recovered and incubated with CEA/P815 cells for 5 days in medium supplemented with IL-2. The cells were then tested for CTL activity. As shown in Figure 3a , treatment with a mixture of pCI-CEA and a blank vector induced a CTL response against CEA/P815. Coinjection of pCI-CEA with either pCI-IFN␥ or VR-IL12 increased anti-CEA/P815 CTL activity considerably, while coinjection of pCI-CEA with pCI-IL4 decreased the CTL activity. In all groups, no CTL activity was seen against parental P815 target cells (not shown).
CEA/P815 cells express neomycin phosphotransferase
Gene Therapy (NPT), having been selected for G418 resistance, and that protein is known to be antigenic in mice. pCI-CEA, pCI-IFN␥ and pCI-IL4 encode NPT, while pCMV, pCMV-CEA and vectors derived from VR1255 (ie blank VR and VR-IL12) do not. pCMV-CEA and pCI-CEA induced comparable levels of CTL activity against CEA/P815 (Figure 3a, b) . Injection of pCI-neo (with blank VR) did not induce CTLs reactive to CEA/P815 (Figure 3a ). However, when pCI-neo was coinjected with VR-IL12, a low level of CTL activity was noted (Figure 3b ), though much less than with CEA-encoding vectors following similar immunization. Thus, it appears that CEA is the main target antigen for CTLs in the anti-tumor response.
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Secretion of IL-4 and IFN␥ by spleen cells in vitro
To determine whether codelivery of cytokine-expressing vectors and CEA vector could influence differentiation of Th cells, and thus influence production of cytokines, we compared the amount of IL-4 and IFN␥ released by spleen cells stimulated with CEA-expressing syngeneic tumor cells. DBA/2 mice were injected i.m. with a mixture of plasmids, ie pCI-CEA and other vectors as shown in Figure 4 . Spleen cells from the immunized mice were recovered and stimulated in culture with CEA/P815 cells. Analysis of supernatants by ELISA revealed that spleen cells from mice coinjected with pCI-CEA and control vector produced substantially more IFN␥ (27-fold increase), and slightly more IL-4, when compared with control mice (pCI-neo + VR). Spleen cells from mice coinjected with pCI-CEA and either pCI-IFN␥ or VR-IL12 had a further increase in the levels of IFN␥ and produced very low levels of IL-4. Spleen cells from mice coinjected with pCI-CEA and pCI-IL4 secreted high levels of IL-4, but reduced levels of IFN␥. In all groups, parental P815 cells did not stimulate cytokine production above spleen cells grown in medium alone (not shown). P815 cells are highly tumorigenic. We also observed this feature with the CEA/P815 cell line. The high tumorigenic potential may explain why immunization with the pCI-CEA vector alone could not completely inhibit tumor growth.
Mice that received a CEA-encoding vector plus either pCI-IFN␥ or VR-IL12 showed much enhanced protection against the tumor challenge. Many of these mice (63% and 75%, respectively) were completely tumor free over 90 days after tumor challenge ( Figure 6a ). As expected, CEA-immunized mice were not protected from native P815 cells ( Figure 5b) .
As demonstrated by average tumor volume (Figure 5a ), mice that received pCI-CEA plus pCI-IL4 showed reduced tumor immunity compared with those that received pCI-CEA plus blank vector, and all died by day 45 (Figure 6a ).
In these experiments, the possibility that NPT contributes to tumor rejection must be considered. However, immunization with pCI-neo which encodes NPT but not CEA (delivered with VR which encodes neither NPT nor CEA and is added as a control for the amount of bacterial DNA injected) did not protect from tumor growth (Figure 5a ) or improve survival (Figure 6a ) more than injection of saline (no DNA). Moreover, when pCI-neo was combined with VR-IL12 there was only a small decline in tumor growth (Figure 5b ), which was not statistically significant versus either blank pCMV + VR treatment (Figure 5c ) or CEA/IL-12-immunized mice injected with native P815 cells (expressing neither CEA nor NPT) (Figure 5b ). Thus, we found no evidence that immunity directed to NPT was protective.
Circulating IL-12 does not enhance immunity to CEA/P815 Since it has been reported that IL-12 has strong antitumor effects, 26 we also tested a different manner of delivery of the DNA vaccine and the VR-IL12 vector. In previous experiments, both vectors were injected at the same muscle site; however, mice that received pCI-CEA injected into muscle of one leg and VR-IL12 into muscle of the other leg did not show enhancement of tumor rejection over mice not receiving VR-IL12 (Figures 5a, b,  and 6a, b) .
Delivery of IL-12-expressing plasmids alone, without pCI-CEA immunization, could not inhibit tumor growth either (Figures 5a and 6b) . Serum samples from mice injected with VR-IL12, with or without other vectors, were tested for the presence of serum IL-12 by ELISA. In all cases, VR-IL12 treatment significantly increased both total IL-12 and IL-12p70 serum levels. Before DNA injections mice had levels of total IL-12 = 224.0 ± 9.3 pg/ml and IL-12p70 = 2.4 ± 0.1 pg/ml (n = 25). One week after a series of five weekly vector injections the following serum levels were recorded, expressed as total IL-12 and IL-12p70 (the latter in parentheses) in pg/ml ± s.e.m. (n = 5 per group): pCI-neo + VR treatment = 235.4 ± 6.5 (2.3 ± 0.2); pCI-CEA + VR-IL12 (same muscle site) treatment = 298.2 ± 4.7 (3.7 ± 1.6); pCI-CEA + VR-IL12 (separate muscle sites) treatment = 389.4 ± 2.2 (5.7 ± 0.3); VR-IL12 alone treatment = 398.4 ± 16.2 (5.5 ± 0.2). Only groups of mice receiving VR-IL12 had significantly elevated values of IL-12 (both total and p70 in all cases) versus preimmunization levels in the same groups (P Ͻ 0.001). It is unclear why coinjection of pCI-CEA with VR-IL12 resulted in lower IL-12 levels than separate site injection.
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As reported by others, 27 total IL-12 levels (includes heterodimeric p70, as well as monomeric and dimeric p40) were always much higher than the active IL-12p70 form.
These results indicate that the IL-12 vector must be Figure 6b shows the survival rate in groups of mice described in Figure 5a, injected at the same muscle site as the CEA vector for optimal immunization. Moreover, in the absence of CEA immunization, circulating IL-12 was insufficient to inhibit tumor growth in this model.
Discussion
CEA seems to be a weak immunogen in humans and in mice. 14, [28] [29] [30] [31] [32] [33] Low levels of CEA-specific antibody and T cell responses have been found in some of the patients immunized with recombinant baculovirus CEA (bV-CEA) in alum, while combination with granulocytemacrophage colony-stimulating factor (GM-CSF) improved the immune responses. 28 In mice, Irvine et al 29 reported that they could not detect cytotoxic T cell responses to CEA-transduced tumor cells following immunization with purified native CEA emulsified in complete Freund's adjuvant. Bei et al 30 also reported that three injections of bV-CEA emulsified in Detox adjuvant did not induce the rejection of a transduced CEA-positive cell line. In several murine models, multiple immunizations were required to achieve immunity against syngeneic tumor cells expressing CEA. 21, 31 Thus, CEA represents an example of a weak immunogen for which effective immunization strategies need to be explored.
Consequently, efforts have been made to improve anti- 33 showed that use of a cationic liposome formulation (DOTAP) as an adjuvant increased antitumor effect elicited by the bV-CEA vaccine. However, DNA vaccines provide a potent alternative to these methods, as shown by Conry and colleagues. 21 In this respect, codelivery of cytokine genes may represent an effective approach to enhance or regulate immune responses. Notably, It has been shown that plasmids encoding a single cytokine such as IL-12, IL-2, or GM-CSF were effective at augmenting antigen-specific immune responses elicited by DNA vaccines. [34] [35] [36] In this study, we addressed the following issues: (1) can the immune responses elicited by a DNA vaccine for a weak immunogen, such as CEA, be enhanced by i.m. coinjection of plasmids encoding various cytokines; (2) can the type of T cell response (eg Th1, Th2, or CTLs) and protective tumor immunity elicited by the DNA vaccine be modulated by this method; and (3) can circulating IL-12 alone enhance antitumor immunity in this model? We constructed a plasmid encoding human CEA for use as a DNA vaccine (pCI-CEA), and plasmids expressing the murine cytokines IFN␥, IL-12, and IL-4 to be used as genetic adjuvants in the context of pCI-CEA DNAbased vaccination.
Our choice of cytokines was influenced by the fact that IL-12 and IFN␥ are important enhancers of Th1-type responses. 37 Moreover, IL-12 inhibits angiogenesis which is required for tumor growth, 38 enhances macrophage activity via increased production of IFN␥, 39 and stimulates CTL and NK cell activity. 40 Conversely, IL-4 stimulates the differentiation of Th2 cells and inhibits the development of Th1 cells. 41 It also inhibits activation of macrophages by IFN␥. 42, 43 IL-4 promotes B cell growth and induces isotype shift in B cells (IgG1 and IgE production). 44 We found that coinjection of the CEA DNA vaccine with a plasmid encoding IFN␥ or IL-12 promoted CEAspecific IgG2a production, and enhanced anti-CEA/P815 CTL activity. In vitro, spleen cells of treated mice showed increased CEA/P815-stimulated IFN␥ production. On the other hand, coinjection of the DNA vaccine with a plasmid encoding IL-4 resulted in an increase in anti-CEA IgG1 production, but reduced IgG2a, and reduced anti-CEA/P815 CTL responses. There was increased IL-4 secretion by CEA/P815-stimulated spleen cells. Thus, codelivery of the DNA vaccine with a vector encoding IFN␥ or IL-12 promoted the development of a Th1-dominant response, while codelivery of the DNA vaccine with a vector encoding IL-4 induced a Th2-dominant response.
In the CTL assay, killing is unlikely to be mediated by NK cells for two reasons. First, P815 cells are NK resistant, though they can be killed by lymphokine-activated killer (LAK) cells. Second, cell lysis was only observed with CEA-transfected P815 (antigen-positive) target cells. Since NK and LAK cells are not antigen specific, they should kill both native P815 and CEA/P815 cells. In interpreting our cytokine secretion results we must consider the possibility that plasmids could have gained access to the spleen and influenced in vitro results. However, this seems unlikely, since by PCR analysis we find that only small amounts of plasmid can be detected outside muscle following i.m. injection (our unpublished Gene Therapy observations). Furthermore, cytokine secretion by spleen cells in vitro required stimulation with CEA/P815 cells as a source of antigen. Cytokines were only present at background levels in the supernatants of spleen cells grown without CEA/P815, which argues against vector driven production independent of T cell stimulation.
To test the anti-tumor efficacy of the vaccination, CEAexpressing P815 mastocytoma cells of DBA/2 origin (CEA/P815) were transplanted into DBA/2 mice. The mice injected with saline (no DNA) or with control vectors had tumor growth, which could be observed as early as 10 days. None of these mice survived, and evidently transplantation of CEA-expressing P815 tumor cells into the unimmunized syngeneic mice could not elicit an effective protective immune response. The mice immunized with the CEA-encoding DNA vaccine, without a cytokine-expressing plasmid, had only partial inhibition of tumor growth and most died by 60 days. Mice injected with pCI-CEA plus pCI-IL4 had reduced tumor immunity, compared with pCI-CEA treatment alone. Moreover, weak tumor immunity in IL-4-treated mice was accompanied by lowered anti-CEA/P815 Th1 and CTL responses. Clearly, IL-4 inhibited the T cell-mediated responses thought to be protective in this model.
In contrast, mice immunized with pCI-CEA plus either IFN␥-or IL-12-expressing plasmids showed significantly enhanced inhibition of tumor growth. Many of these mice (62.5% and 75%, respectively) were completely tumor free over 90 days after tumor challenge. These results paralleled the increased Th1 and CTL activity induced by the cytokine-encoding vectors. In our experiments, IFN␥ and IL-12 vectors were almost equally effective at inducing Th1 responses and CTL activity, or inhibiting tumor growth. Although we did not address this question, we speculate that IL-12 acts at least partially by enhancing IFN␥ secretion.
The plasmids pCI-CEA, pCI-IL4 and pCI-IFN␥ contain the NPT gene (neomycin resistance or neo), and NPT is an immunogenic protein in mice. The CEA-positive P815 stable transfectant cell line (CEA/P815) used in our experiments produces this molecule, since it was selected for G418 resistance. Therefore, the question arises as to whether NPT is a rejection antigen in our experiments. Vaccination with either pCMV-CEA (NPT-negative) or pCI-CEA was equally effective at inhibiting tumor growth and inducing anti-CEA/P815 CTLs. Immunization of mice with the pCI-neo vector did not induce CTL activity against the CEA/P815 cell line, except for low levels when it was coinjected with VR-IL12. This CTL activity was much lower than observed with CEA-encoding vectors following similar immunization. Spleen cells of pCI-neo-immunized mice only produced low interferon-gamma levels in vitro following stimulation with these cells, unlike the cells of mice immunized with pCI-CEA. Moreover, pCI-neo, even when coinjected with VR-IL12, did not significantly enhance resistance to a tumor challenge. In these experiments, VR is a non-CEA/non-NPT containing vector which was added as a control for the amount of bacterial DNA injected.
Thus, it appears that CEA is the main target antigen of the anti-tumor response. The reason for the lower immunogenicity of NPT in our experiments is unclear, though the fact that it is strictly a cytoplasmic antigen (unlike CEA that can also be expressed on the membrane) may be a factor. A recent study 10 revealed that following
Gene Therapy i.m. injection of ovalbumin (OVA) expression plasmids, secreted or membrane-bound forms of OVA generated stronger CTL responses than a cytoplasmic form. It is postulated that these differences result from altered antigen uptake or processing by APCs. Since P815 is itself an immunogenic tumor, part of the antitumor response could be directed against native P815 tumor antigens. Such responses may have occurred but did not protect the mice from tumor progression and death. Recently, we have transplanted a different tumor cell line, ie CEA-transfected Lewis lung carcinoma of the mouse. Though this tumor cell line is aggressive and not notably immunogenic on its own, pCI-CEA immunization of syngeneic C57BL/6 mice (with or without cytokine vectors) yielded protective immunity very similar to that reported here against CEA/P815 (K Song and G Prud'homme, manuscript in preparation). Thus, P815 tumor antigens are not required for tumor rejection in our model. A limitation of our study is that CEA is not an endogenous antigen in mice. In future studies, it will be interesting to determine if immune responses can be generated against murine tumor-associated antigens by this DNA vaccination method.
IL-12 is known to be a potent anti-cancer agent. The antitumor efficacy of IL-12 has been demonstrated in a variety of tumor models by all of the following: systemic administration of recombinant IL-12 protein; 45 local delivery of IL-12 at the tumor site using genetically modified fibroblasts 46 or tumor cells; 47 recombinant viral vector delivery; 48 or gene gun-delivered IL-12-encoding plasmid DNA. 49 To determine whether i.m. injection of the IL-12-encoding vector could act solely through elevated circulating IL-12 levels, we injected the IL-12-encoding vector, with or without pCI-CEA, in various ways (eg DNA vaccine in the right leg, IL-12 vector in the left leg). We found that when the CEA-expressing and IL-12-expressing plasmids were simultaneously delivered at different muscle sites (opposite legs), there was no enhancement of tumor immunity. Similarly, injection of the IL-12 vector alone (no pCI-CEA) was ineffective, even though these mice had higher circulating IL-12 than the mice coinjected with both pCI-CEA and IL-12 vector at the same site. IFN␥ was not detected in the serum of any of these mice. However, though serum total IL-12 levels were increased by 70-170 pg/ml, the levels of the active heterodimeric form of IL-12, IL-12p70, were only increased by a few pg/ml, which is perhaps too little to inhibit tumor growth.
Recently, Schults J et al 27 have reported that i.m. injection of an IL-12-encoding plasmid different from ours generates strong antimetastatic activity to the malignant melanoma cell line B16-F10. I.m. injection with 100 g of their IL-12 expression plasmid produced approximately 35 pg/ml of serum IL-12p70. These levels are much higher than achieved in our study. However, as in our study, total IL-12 levels (IL-12p70, plus monomeric and dimeric p40) were much higher than the active IL-12p70 form. The significance of a high total IL-12/IL-12p70 ratio is unclear, though p40 dimer has been shown to have inhibitory effects. At any rate, it is clear that in our model the IL-12-induced enhancement of immunity cannot be attributed to circulating IL-12. Local effects, presumably either in the muscle or draining lymph nodes, appear to be important.
The local effects of cytokine-expressing plasmids are not well understood, but could be related to a number of phenomena. By immunohistochemical analysis, we find that CEA is produced by muscle cells for 2-4 weeks following a single DNA injection of pCI-CEA (unpublished observation). Usually, at the site of injection, only 3-5% of muscle cells produce the antigen at a detectable level. Following i.m. injection of antigen-encoding plasmids, we find that the decline in protein expression correlates with accumulation of a lymphocytic infiltrate, can be delayed by an anti-inflammatory cytokine, and is much slower in immunodeficient SCID mice (C Piccirillo and G Prud'homme, manuscript submitted for publication).
Several reports have demonstrated the important role of bone marrow-derived cells in antigen presentation and CTL induction following DNA vaccination. [50] [51] [52] It seems likely that the adjuvant effect of the plasmids requires secretion of these cytokines in close proximity to the APC, or interacting T cell/APC aggregates, or perhaps directly by the same APC that is presenting CEA to T cells. This is akin to the findings of Conry et al, 53 who reported that the costimulatory molecule B7-1 had to be expressed by the same vector as CEA, and presumably the same APCs, for enhancement of immunity. However, in that case B7-1 is a membrane-bound molecule. Interestingly, Behrens et al 54 found that after stimulation with IFN␥, human muscle cells express a functional costimulatory molecule BB-1 that plays a role in antigen presentation. This molecule is similar but not identical to B7-1 and B7-2. However, the significance of this is unclear, since professional APCs (macrophages, dendritic cells, B cells) are thought to be essential for DNA vaccination. In any case, it is well established that cytokine stimulation of APCs influences their costimulatory activity. 55 Furthermore, locally secreted cytokines may act directly on CD4 + T cells to induce differentiation into Th1 or Th2 cells. Similarly, locally produced cytokines could induce differentiation of CTL precursors into mature CTLs.
It has been found that unmethylated CpG dinucleotide motifs present in plasmid can function as an adjuvant. 56 However, in our study blank vectors do not mimic the immunostimulatory effects of cytokine-encoding vectors. Thus, though bacterial DNA is known to have an adjuvant effect, this cannot replace or match the strong adjuvant effects we are reporting with cytokine vectors.
To our knowledge, this is the first report showing that the i.m. coinjection of a CEA-expressing plasmid with cytokine-expressing plasmids biased the type of CEAspecific immune response (Th1 versus Th2). The CEA cDNA and cytokine cDNA were encoded by separate expression plasmids. Moreover, enhancement of CEAspecific CTL activity was detected in our model, but not in others. 53 Our ability to generate CTLs may be related to many factors including the type of vectors used for immunization, method of in vitro restimulation of T cells, and the type of target tumor cells. Interestingly, IFN␥ and IL-12 were almost equally effective at inducing these cells, while IL-4 was inhibitory.
Our results showing negative effects of IL-4 on tumor immunity contrast with some reports of protective effects. 57, 58 However, in most of these experiments IL-4 is produced locally by the tumor cells. It is unclear how IL-4 protect tumors in these cases, but this is a situation clearly different from DNA-based immunization in muscle. For example, local production of IL-4 by tumor cells, even in nude mice, results in eosinophil accumulation and eosinophil-mediated cytotoxicity. 57 For unclear 489 reasons, IL-4 can display a direct antitumor effect as shown in human colonic, renal, gastric, and breast tumors, as well as leukemia. 58 This cytokine can also stimulate B cells to produce antibodies which may be relevant in some tumor models. In our case, however, protective immunity probably depends on effector T cells induced by vaccination either in the muscle or (more likely) draining lymph nodes. If Th1 cells and CTLs are the main mediators of tumor rejection it is not surprising that IL-4 has detrimental effects.
Cytokines such as GM-CSF, IFN␥, IL-4 and others can skew immune responses by acting on the APC. This may alter antigen presentation, cytokine/chemokine secretion, and either stimulate or inhibit macrophage effector functions. Some cytokines (particularly IL-12 and IFN␥) have pleiotropic proinflammatory effects that can contribute to tumor cell killing. Thus, in situ cytokine production by tumor cells may have several effects not duplicated by DNA vaccination.
On the other hand, it is clear that inflammatory cytokines such as IFN␥ are not always beneficial in DNA vaccination studies. Notably, in an i.m. DNA vaccination study Xiang and Ertl 59 found that while GM-CSF enhanced B cell and T cell responses to a rabies virus antigen, IFN␥ had the opposite effect. It is difficult to compare this situation with a tumor model, but it has to be considered that the positive effects of DNA vaccination in various models may be mediated primarily by either antibodies, Th1 cells, Th2 cells, CTLs, or macrophages. Thus, IFN␥ may inhibit a protective Th2-dependent response.
Administration of cytokine-encoding plasmids in combination with DNA vaccines may serve as a simple and effective way of generating an adjuvant effect. This may provide a sustained but relatively low level of cytokine secretion, without the undesirable side-effects frequently caused by the systemic administration of boluses of cytokine protein. In our experiments circulating levels of active IL-12 were very low. This is relevant, since this cytokine can have severe toxic effects. Furthermore, cytokine therapy allows regulation of immunity to either predominant Th1 or Th2 types. This approach to vaccination has the potential for applications in many infectious, neoplastic or autoimmune diseases.
Materials and methods
Plasmid construction cDNA containing the complete coding sequence for CEA was inserted into pCI-neo (Promega, Madison, WI, USA), which contains the human cytomegalovirus (CMV) immediate-early enhancer/promoter, a chimeric intron, and the SV40 poly (A) signal sequence. The resulting pCI vector encoding CEA was then designated pCI-CEA (Figure 1 ). pCMV and pCMV-CEA lack the neo expression cassette but are otherwise identical to pCI-neo and pCI-CEA, respectively. Complete cDNA sequences of mouse IFN␥ and IL-4 were inserted into pCI-neo to produce vectors designated pCI-IFN␥ and pCI-IL4, respectively (Figure 1) .
The p35 and p40 cDNA sequences of murine IL-12 were cloned into the bicistronic expression vector pIRES1neo (Clontech Bio/Can Scientific, Mississauga, Ontario, Canada) to produce a vector designated pIRES-IL-12. The
Gene Therapy segment, consisting of p35 cDNA, the synthetic intron (IVS), the IRES sequence, and p40 cDNA, was then subcloned into the plasmid VR1255 60 (kindly provided by VICAL Inc, San Diego, CA, USA), after removal of the luciferase gene, to produce a vector designated VR-IL12. The VR1255 vector also contains the human CMV immediate-early enhancer/promoter, a CMV intron A, and the minimal rabbit beta globin poly (A) signal sequence. An empty VR1255-derived vector, designated VR, was used as a control in several experiments.
Transfection of COS-7 cells and detection of CEA and cytokines To confirm production of the CEA, IFN␥, IL-4, and IL-12 directed by the respective plasmids, COS-7 cells (ATCC CRL 1651) were transiently transfected with each of the vectors. The presence of IFN␥, IL-4, or IL-12 p70, in supernatant was confirmed and quantitated by ELISA assays (see next section).
Cell surface expression of CEA by pCI-CEA-transfected COS-7 cells was analyzed by immunofluorescence staining and flow cytometry analysis using an anti-CEA mAb (from hybridoma clone B18, kindly provided by Dr Abraham Fuks, McGill University, Montreal, Canada) and a goat anti-mouse IgG-FITC conjugate (Sigma Chemical, St Louis, MO, USA).
ELISA assays
Cytokine levels in culture supernatants or mouse serum samples were determined by ELISA as follows: concentrations of IFN-gg and IL-4 were measured by ELISA kits (R&D Systems, Minneapolis, MN, USA; detection limit Ͻ2 pg/ml, both assays); according to the manufacturer's instructions. IL-12 levels were measured either with the mouse total IL-12 ELISA kit (Genzyme, Cambridge, MA, USA; detection limit = 10 pg/ml), which detects all three forms of IL-12 (p70 heterodimer, p40 homodimer, and p40 monomer), or with the mouse IL-12 p70 ELISA kit (R&D Systems; detection limit Ͻ2.5 pg/ml), which detects the p70 heterodimer only.
Plasmid DNA preparation Plasmid DNA was prepared by the alkaline lysis method using the Qiagen kits (Qiagen, Santa Clarina, CA, USA), according to the manufacturer's instructions. DNA prepared for i.m. injections was dissolved in sterile 0.85% NaCl and stored at −80°C. Spectrophotometric analysis revealed 260/280 nm ratios у1.80. Purity of DNA preparations and conformation was confirmed by electrophoresis with 1% agarose gel.
Establishment of the CEA transfected mouse tumor cells A mouse mastocytoma cell line, P815 (ATCC TIB64), of DBA/2 origin was used for establishment of a CEAexpressing stable transfectant cell line. To facilitate efficient production of stable transfectant lines, CEA cDNA from pCI-CEA vector was transferred into the bicistronic expression vector pIRES1neo. Stable transfectant clones were generated from CEA-positive cultures, and the P815 cells expressing CEA were designated CEA/P815. These cells were used in cytotoxicity assays and in in vivo tumor challenge experiments. Expression of CEA on at least two-thirds of cells was reconfirmed before use in each experiment.
Gene Therapy
Immunization of mice Six-week old female DBA/2 mice (H-2 d ) were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). Unless indicated otherwise, 6-to 8-week old mice were anesthetized and injected i.m. in the rectus femoris muscles, with one injection in each leg consisting of 50 g CEA-plasmid (100 g of DNA per mouse), mixed with either 100 g of a blank VR (200 g of DNA per mouse) or 100 g of a cytokine-encoding vector (200 g of DNA per mouse), in saline, injected at a volume of 75 l per muscle site using a disposable sterile plastic insulin syringe and 29G1/2 needle (VWR Canlab, Mississauga, Ontario, Canada).
Quantitation of CEA antibody Serum samples were assayed for the presence of anti-CEA antibodies by a cellular enzyme-linked immunoabsorbent assay (CELISA). The CEA-producing human adenocarcinoma cell line LS180 (kindly provided by Dr Abraham Fuks, McGill University) was used as a CEA antigen source in the assay. Briefly, 96-well plates were coated with 2 × 10 5 of LS180 cells in 50 l of HBSS containing 0.5% formalin (Fisher Scientific, Los Angeles, CA, USA) and incubated at 37°C overnight. The rest of the steps were performed at room temperature. After washings with washing buffer (PBS supplemented with 0.5% Tween 20), wells were blocked with 3% BSA in PBS containing 0.5% Tween 20 for 1 h. As a second layer, diluted serum samples, or as a standard dilutions of an anti-CEA mAb, were applied to the plate for 1 h. After additional washings, a third layer consisting of either goat-anti mouse IgG (Cedarlane Laboratories, Hornby, Ontario, Canada), goat-anti mouse IgG1 (Cedarlane Laboratories) or goat-anti mouse IgG2a (Cedarlane Laboratories) was applied to the plate. The plate was washed again, and the fourth layer consisting of rabbit anti-goat IgG conjugated with alkaline phosphatase (BioRad Laboratories, Hercules, CA, USA) was added to the plate. The reaction was developed and read according to the manufacturer's instructions. Concentrations of total IgG anti-CEA Ab and the isotypes IgG1 and IgG2a Abs were calculated from the standard curve generated by appropriate anti-CEA mAbs and results are reported as units (U), where 1 U of anti-CEA antibody = 1 g of anti-CEA mAb.
Cytotoxicity assay
Spleen cells (4 × 10 6 per well) were first cultured with irradiated (12 Gy) CEA/P815 cells (4 × 10 6 per well) in medium consisting of RPMI 1640 (Gibco BRL), containing 10% FBS, and supplemented with 20 U/ml human rIL-2 (MEDICORP, Montreal, Quebec, Canada) in 24-well plates at 37°C for 5 days, for in vitro stimulation of the responder spleen cells. To perform the chromium-release assay, target CEA/P815 cells and parental P815 tumor cells (2 × 10 6 cells) were labeled with 200 Ci of Na 2 51 CrO 4 (Amersham, Oakville, Ontario, Canada) for 90 min at 37°C, followed by three washes. The target cells and the in vitro stimulated responder cells, both resuspended in medium, were then combined at various effector-to target ratios in 96-well, U-bottom plates (Fisher Scientific, Whitby, Ontario, Canada) in a volume of 200 l per well. After a 6-h incubation at 37°C, 100 l of supernatant was harvested from each well and radioactivity was quantitated in a gamma counter (Beckman Instrument, Fullerton, CA, USA). The percent specific lysis was calculated using the following equation: percent specific lysis = [(experimental release − spontaneous release)/(maximum release − spontaneous release)] × 100. Spontaneous release was determined by incubation of target cells in the absence of effector cells. Maximum release was determined by incubation of target cells in 1% Triton X-100. P815 cells are not lysed by NK cells.
Cytokine release assay For measuring cytokine release by lymphoid cells of mice, spleen cells from the experimental or control animals were cultured with irradiated CEA/P815 or parental P815 cells in 24-well plates, in the same conditions described above for the cytotoxicity assay, except that the culture was maintained for 3-4 days. Then cell-free supernatants were harvested and stored at −80°C. The supernatant samples were assayed for the presence of IFN␥ and IL-4 by ELISA.
Tumor cell challenge
One week after the last of five immunizing DNA injections, DBA/2 strain mice were transplanted with 1 × 10 6 CEA/P815 cells by subcutaneous injection into the left flank. Tumors were measured by caliper in two dimensions and the volumes were calculated using the formula (width 2 × length)/2. In addition, survival of mice was determined. Moribund mice with large tumors were killed.
Statistical analysis
The statistical significance of differences among various groups of mice for all data, except survival, was determined by analysis of variance. Survival of mice injected with tumor cells was plotted using the Kaplan-Meier method (nonparametric cumulated survival plot), and statistical comparison between the curves obtained using the log rank test. All analyses were done with the SYS-TAT statistical software (version 8.0, SPSS Inc, Chicago, IL, USA).
